Literature DB >> 27677622

Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.

Lisete Ribeiro Teixeira1, Murilo B Dias2, Roberta K B Sales2, Leila Antonangelo2,3, Vanessa A Alvarenga2, Juliana Puka2, Evaldo Marchi2,4, Milena Marques Pagliarelli Acencio2.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are responsible for the breakdown of the extracellular matrix and play an important role in the inflammatory processes of pleural exudates. The imbalance between MMPs and their inhibitors (TIMPs) is present in various pathological processes.
OBJECTIVE: To evaluate the profile of MMPs and TIMPs in pleural effusions of different etiologies correlated with inflammatory markers.
METHODS: The patients with pleural effusion due to tuberculosis (TB), cancer (CA) or transudate were prospectively evaluated. Pleural fluid was submitted to cytological, biochemical, cytokines, MMP, and TIMP analysis. Statistical analysis was performed using ANOVA and Spearman's correlation, and p < 0.05 was considered significant.
RESULTS: One hundred and fourteen patients were enrolled, 80 exudates (41 TB and 39 CA) and 34 transudates. The levels of MMP-8 and MMP-9 were higher in exudates compared to transudates. The level of MMP-8 was significantly higher in TB than in CA. TIMP-1 levels were higher in exudates. IL-6, VEGF, and TGF-β1 showed differences between exudates and transudates. However, IL-6 level was higher in TB than in CA. We found a significant correlation between MMPs and TIMPs with inflammation markers. MMP-1 was correlated with LDH levels. MMP-8 was correlated with LDH, total cell count, neutrophils, and ADA as well as MMP-1 levels. MMP-9 was correlated with IL-6, TGF-β1, and VEGF. TIMP-1 was correlated with MMP-9 and IL-6.
CONCLUSIONS: MMPs and TIMPs are expressed in pleural fluid of different etiologies and correlate with inflammatory mediators. MMPs may be useful in determining the cause of fluid, but more studies are needed to determine the spectrum of diseases associated with the various isoforms of MMPS and TIMPs.

Entities:  

Keywords:  Cancer; Matrix metalloproteinases; Pleural effusion; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27677622     DOI: 10.1007/s00408-016-9945-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  35 in total

Review 1.  Gelatinase B: a tuner and amplifier of immune functions.

Authors:  G Opdenakker; P E Van den Steen; J Van Damme
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

Review 2.  The matrix metalloproteinases and their inhibitors.

Authors:  G Murphy; A J Docherty
Journal:  Am J Respir Cell Mol Biol       Date:  1992-08       Impact factor: 6.914

Review 3.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

Review 4.  Cytokines. 2. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lung.

Authors:  R M Strieter; N W Lukacs; T J Standiford; S L Kunkel
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

Review 5.  Pathophysiology of pleural space infections.

Authors:  V B Antony; K A Mohammed
Journal:  Semin Respir Infect       Date:  1999-03

6.  MMP and TIMP expression pattern in pleural effusions of different origins.

Authors:  O Eickelberg; C O Sommerfeld; C Wyser; M Tamm; F Reichenberger; P G Bardin; M Solèr; M Roth; A P Perruchoud
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

7.  Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.

Authors:  S C Pritchard; M C Nicolson; C Lloret; J A McKay; V G Ross; K M Kerr; G I Murray; H L McLeod
Journal:  Oncol Rep       Date:  2001 Mar-Apr       Impact factor: 3.906

8.  Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions.

Authors:  D Iglesias; J Alegre; C Alemán; E Ruíz; T Soriano; L I Armadans; R M Segura; A Anglés; J Monasterio; T Fernández de Sevilla
Journal:  Eur Respir J       Date:  2005-01       Impact factor: 16.671

9.  High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation.

Authors:  P Sheen; C M O'Kane; K Chaudhary; M Tovar; C Santillan; J Sosa; L Caviedes; R H Gilman; G Stamp; J S Friedland
Journal:  Eur Respir J       Date:  2008-08-20       Impact factor: 16.671

10.  Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease.

Authors:  R Sepper; Y T Konttinen; Y Ding; M Takagi; T Sorsa
Journal:  Chest       Date:  1995-06       Impact factor: 9.410

View more
  6 in total

1.  Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

Review 2.  Neutrophils in Tuberculosis: Heterogeneity Shapes the Way?

Authors:  Irina V Lyadova
Journal:  Mediators Inflamm       Date:  2017-05-24       Impact factor: 4.711

Review 3.  Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.

Authors:  Michal Mierzejewski; Piotr Korczynski; Rafal Krenke; Julius P Janssen
Journal:  Respir Res       Date:  2019-11-07

4.  A meta-analysis of Th1 and Th2 cytokine profiles differentiating tuberculous from malignant pleural effusion.

Authors:  Yulin Zeng; Liwei Wang; Hai Zhou; Yu Qi
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

5.  Aberrant plasma MMP and TIMP dynamics in Schistosoma - Immune reconstitution inflammatory syndrome (IRIS).

Authors:  Odin Goovaerts; Pauline N M Mwinzi; Erick M O Muok; Ann Ceulemans; Robert Colebunders; Luc Kestens
Journal:  PLoS Negl Trop Dis       Date:  2018-08-08

Review 6.  Inflammation of the Pleural Cavity: A Review on Pathogenesis, Diagnosis and Implications in Tumor Pathophysiology.

Authors:  Georgia Karpathiou; Michel Péoc'h; Anand Sundaralingam; Najib Rahman; Marios E Froudarakis
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.